#Experimental and Clinical Transplantation Journal

[indizombie]

Director of National Organ & Tissue Transplant Organisation (NOTTO) Dr Anil Kumar said more men are cadaver donors but more women are living donors. "Of the total organ donations in the country, 93% were living donors. This by itself is a statement that many organ donors in the country are women donors," he said. A paper published in Experimental and Clinical Transplantation Journal in 2021 found a huge gender disparity in the country. The data analysed organ transplants in 2019 and found that 80% of the living organ donors are women, mainly the wife or the mother, while 80% of the recipients are men.

Steffy Thevar, ‘4 of 5 living organ donors in India are women, 4 of 5 recipients men: Study’, Times of India

[she-is-ovarit]

Data spanning from 1995 to 2021 in India revealed a striking gender imbalance in organ transplants, with four men getting organ transplants for every woman. A total of 36,640 transplants took place in this period, out of which 29,000 were for men and 6,945 for women.

This substantial difference is attributed to a complex interplay of economic responsibilities, societal pressures, and deeply ingrained preferences. 

Dr Anil Kumar, director of the government-run National Organ & Tissue Transplant Organisation (NOTTO) highlighted this significant aspect of the organ donation landscape.

While more men contribute as cadaver donors, a staggering 93 per cent of total organ donations in the country come from living donors, he told the Times of India newspaper. This hints at a trend: a majority of living organ donors are women.  Socio-economic factors a driving force for women donors? A study published in the Experimental and Clinical Transplantation Journal in 2021 delved into the intricacies of living organ transplantation in India. The findings showed that 80 per cent of living organ donors are women, predominantly wives or mothers. The socio-economic pressure on women to assume caregiving roles within the family emerges as a primary factor, compelling them to step forward as donors. Men's reluctance in surgery In many cases, men, often the primary breadwinners, hesitate to undergo surgery, contributing to the gender gap in organ recipients. The study highlights that when the recipient is a male breadwinner, family members, especially wives or parents, feel a heightened responsibility to donate organs. Emotional dynamics The emotional dynamics surrounding organ donation are intricate. Women recipients, in particular, may experience guilt when their family members, especially wives or mothers, become donors. This reluctance leads to a scenario where women recipients may find themselves on waiting lists.  Notably, Karnataka has topped the charts in organ donation in the past decade. The number of donations have risen from 102 in 2013 to 765 in the first 10 months of 2023. 

A user on Ovarit added this helpful context:

"Just a little more context to this: men produce male-specific proteins (on the Y chromosome) which often get rejected by women's bodies. Since males have an X chromosome, their bodies recognize proteins from female donors. This makes it more difficult for women to receive male tissue/organs, while still being acceptable candidates for donating to men. Even still, these ratios are very disproportionate".

"As women we absolutely need to be aware of our vulnerability of being used as spare parts in a man's world. Especially when we are being socialized into believing that we need to sacrifice our bodies and lives for others- and society has developed a sense of entitlement to this sacrifice, while downplaying the suffering of women."

[coochiequeens]

some men are more generous after death.

Pune: For every woman who received an organ, four men got transplants in the country. Data from 1995 to 2021 shows 36,640 transplantations were carried out, of which over 29,000 were for men and 6,945 were for women

The stark difference, experts said, was because of economic and financial responsibilities, societal pressures and ingrained preferences.

Director of NOTTO Dr Anil Kumar said more men are cadaver donors but more women are living donors. “Of the total organ donations in the country, 93% were living donors. This by itself is a statement that many organ donors in the country arewomen donors,” he said.

A paper published in Experimental and Clinical Transplantation Journal in 2021 found a huge gender disparity in the country when it comes to living organ transplantation.

The data analysed organ transplants in 2019 and found that 80% of the living organ donors are women, mainly the wife or the mother while 80% of the recipients are men. The study also found that the primary reasons for more women donors are the socio-economic pressure on them to be the caretakers and givers in the family and as men are the bread winners in most cases, they hesitate from undergoing any surgery. Mayuri Barve, an organ transplant coordinator from DY Patil Medical College, Hospital and Research Centre in Pune, said that in the last 15 years that she has been working in this field, only once did a husband come forward to donate his organ to his wife.

Usually, wives,  mothers and even fathers donate, she added.

She said mothers and fathers are happy donors to their children. When both are unavailable, wives come forward. Often, if the daughter is unmarried, she becomes the donor.

See rest of article

[nursingwriter]

¶ … Journal of Clinical Infectious Diseases released the findings of a group of stem-cell researchers working on improving the recovery of leukemia patients that received stem cell transplantations, in the article "Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation." The hypothesis of the study conducted was that Ciprofloxacin would be an effective treatment against a certain virus that affects patients, called Polyoma BK virus, or BKV, which is associated with hemorrhagic cystitis, a kind of serious bladder infection. The hypothesis was found to be true, and the antibiotic Ciprofloxacin will undergo further studies and clinical applications to determine the most effective uses against the BKV in post stem-cell transplant patients. Allogeneic hematopoietic stem cell transplantation is a common treatment used to treat leukemia. This is a type of transplant of stem cells from a donor into the patient, rather than a transplant of one's own stem cells. These stem cells are found in bone marrow, and they are the progenerators of red cells, white cells, and platelets, which are the three major blood elements. It is defects in the creation of these blood cells which causes leukemia, therefore transplanting new stem cells to create healthy blood can save lives. Unfortunately, this transplantation of stem cells must usually be accompanied with high levels of systemic chemoradiation therapy in order to destroy the patient's own bone marrow so that the transplanted bone marrow will work. Hemorrhagic cystitis, or sudden appearance of blood in the urine accompanied by an irritated bladder, is a common symptom in post-transplant patients. It is common in large part because of the chemotherapy drugs which are broken down by the body and then passed through the bladder and urinary system, causing irritation and a weakened immune system. BKV is commonly associated with this bladder condition. Patients undergoing treatment for this bladder condition that tested positive for this virus, after transplantation, were given either ciprofloxacin or a cephalosporin as an antibiotic. The urine was sampled every week, and levels of the virus itself and in vitro drug sensitivity were tested. Ciprofloxacin was in fact found to decrease urinary BKV reactivation. This study affects my daily life in several ways. First, I lost a cat to feline leukemia several years ago, and I have a friend who has been diagnosed with leukemia recently. While this study is relevant to human leukemia, not feline, it is still an advancement for both of these individuals. Treatments that are reserved for humans today, once commonplace enough, will also be available for other animals. However, for my friend who is about to start undergoing chemotherapy treatment and a stem-cell transplant, this is very relevant to me. The many painful side effects of leukemia treatments can be the worst part of the entire ordeal for many patients, and research which confirms the use of a safe antibiotic that will help alleviate and cure some of these very dangerous side effects is a positive application of science. A more pertinent to ethics and morality way in which this is relevant to my everyday life is that this is a prime example of an application of stem cell research that is overlooked by the media. In reference to leukemia treatments, the media always says "bone marrow transplant" and leaves out any mention of stem cells. Stem cells are mentioned most often in controversial debates about the morality of abortion, human experimentation, cloning, and a series of other issues. However, people who demand an end to all stem cell research have completely ignored the fact that many stem cells, which are vital to saving lives, are obtained from willing, living, and consensual donors without any involvement of sci-fi-like or blasphemous technology. People with moral dilemmas regarding some types of stem cell research need to do some research of their own so that they might understand that stem cells are not necessarily (or often, if ever) obtained from some of the objectionable sources people have been led to think. Work Cited Anskar, Y.H., et al. (2005, February 15) Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clinical Infectious Diseases, 40.4. 528(10).  https://www.paperdue.com/customer/paper/journal-of-clinical-infectious-diseases-64611#:~:text=Logout-,JournalofClinicalInfectiousDiseasesreleasedthe,-Length2pages Read the full article

[catilus]

A sinister doctor and his growing army of skeletons I drew on commission! More fantasy art, NPCs, awesome homebrew, and other cool stuff: https://www.patreon.com/Catilus

Character: Dr. Floridius Ohgden, Medical Practitioner and Necromancer

Floridius began his career as a surgeon before becoming an adventurer as he sought a method of eternal life for those not blessed with immortal flesh to go along with their immortal souls. This search led the doctor down a dark path as he sought out the secrets of life and death through experimentation. He would partner up with a rogue doctor running an illegal vivisection clinic where subjects were surgically experimented upon for increasing the pair’s medical knowledge. Eventually Floridius was arrested and served time in a Waterdeep prison for his crimes and his partner and instructor disappeared without a trace. After years of imprisonment, he was released and made for the fortress of Candlekeep where he would begin his studies anew. In exchange for his stay there he taught a class on biology and anatomy often performing vivisections on creatures for demonstrations... This was not a popular class for many reasons.

After months in Candlekeep, Floridius met a party of adventurers who were seeking a method to transition to the Nine Hells to track down a rogue angel who became an archduke of hell. Floridius saw this as an opportunity to study the immortal flesh of devils to further his studies, and so he requested to tag along, offering his medical expertise to the group as well as his skills with small blades to act as an excellent rogue.

The Hells ended up teaching the mad doctor quite a lot on immortality, but he was also falling further into the depths of corruption as he had met with and exchanged knowledge for knowledge with a bound and then freed flesh-shaping demon. The demon taught Floridius the art of fleshcraft and how to graft monster components onto himself and others.

After the party left the Hells, Floridius had multiple journals of notes on the study of immortality via fleshcraft, surgical replacement of organs, and other less than savory means. But he is no god, and thus his control of the immortal soul and its binding to mortal flesh is limited. So, his next goal was clear: transcend the limitations of his mortal coil, perform the ultimate necromantic rituals to bind his soul to an object, and transplant his organs to a fleshcrafted golem. With this he would become a lich like no other; an immortal flesh golem with the knowledge to grant this gift unto others. However, the pursuit of such ability has forever changed the mad doctor and his studies and research have no place in civilization.

What do you think? :)

Find the full HD version, plus tons of fantasy and SF art, D&D items, my 5e adventures and supplements (FREE for Patreon supporters!), NPCs, and more great stuff at myPatreon: https://www.patreon.com/Catilus

Join the Catilus Discord! https://discord.gg/catilus

Facebook: https://www.facebook.com/CatilusArt

Instagram: https://www.instagram.com/CatilusArt/

Twitter: https://twitter.com/CatilusArt

#Catilus #Patreon #dnd #DnDcharacter #art #fantasy #roleplay #RPG #TTRPG #magic #commission #necromancer #doctor #cute #hotguy

[sciencespies]

Protecting coral from heat stress and coral bleaching

https://sciencespies.com/environment/protecting-coral-from-heat-stress-and-coral-bleaching/

Protecting coral from heat stress and coral bleaching

Corals are the backbone of marine ecosystems in the tropics. They are threatened by rising water temperatures caused by global warming and they are among the first ecosystems worldwide that are on the verge of ecological collapse. Coral bleaching, which is becoming stronger and more frequent due to heat stress, has already wiped out corals at many locations globally. With the help of a microbiome-targeting strategy developed by an international team led by GEOMAR Helmholtz Centre for Ocean Research Kiel, it could become feasible to help protect corals from heat stress. The work has now been published in the international journal Microbiome.

Corals are the backbone of marine ecosystems in the tropics. They are threatened by rising water temperatures caused by global warming and they are among the first ecosystems worldwide that are on the verge of ecological collapse. Coral bleaching, which is becoming stronger and more frequent due to heat stress, has already wiped out corals at many locations globally. With the help of a microbiome-targeting strategy developed by an international team led by GEOMAR Helmholtz Centre for Ocean Research Kiel, it could become feasible to help protect corals from heat stress. The work has now been published in the international journal Microbiome.

Images of bare, naked white coral reefs have been increasingly circulating around the world. The typically colourful reefs of tropical oceans, which are home to many species of the marine ecosystem, are suffering from rising water temperatures due to global warming. There is no heat relieve for the corals in sight. Scientists are desperately seeking out ways to make the temperature-sensitive organisms more resistant to heat stress. A group of scientists led by GEOMAR Helmholtz Centre for Ocean Research Kiel are developing a promising approach, which is based on a therapeutic treatment known from human medicine. The study was published in the international journal Microbiome.

“The idea is that probiotic bacteria with beneficial functions could help a coral to better withstand heat stress,” explains Dr Anna Roik from GEOMAR, lead author of the study, which was funded as part of a Future Ocean Network project at Kiel University. “In the current study, we tested the approach of a ‘microbiome transplantation’, inspired by microbiome-based applications we know for example from clinical treatments,” Roik continues.

The research group conducted coral microbiome transplantation experiments with the reef-building corals Pocillopora and Porites in the Andaman Sea in Thailand. They investigated whether this technique can improve the heat resistance of corals by modifying the bacterial microbiome. The scientists first looked for more heat-tolerant “donor” corals. “We then used material from the coral tissue of the donor corals to inoculate conspecific, heat-sensitive recipients and then documented their bleaching responses and microbiome changes using a genetic analysis method called 16S rRNA gene metabarcoding,” explains Dr Roik.

The recipient corals of both species bleached more mildly compared to the control group during a short-term heat stress test (34 °C). “The results show that the inoculated corals were able to resist the heat stress response for a short time,” explains Prof. Dr Ute Hentschel Humeida, head of the Marine Symbioses Research Unit at GEOMAR and co-author of the study. “In addition, the microbiome data suggest that the ‘inoculated’ corals may favour the uptake of putative bacterial symbionts,” Dr Anna Roik continues. “However, further experimental studies are required to unravel the exact mechanism of action, as well as long-term field-based studies to test the durability of the effect,” says the marine biologist, looking ahead.

Story Source:

Materials provided by Helmholtz Centre for Ocean Research Kiel (GEOMAR). Note: Content may be edited for style and length.

#Environment

[cambridgepublishers]

Journal of Invasive Cardiology Case Reports

Case Reports in Invasive Cardiology Journal Publishes Images in Invasive Cardiology, Clinical Image of Invasive Cardiology, Clinical images in non-Invasive Cardiology, Case Reports of Non-invasive Cardiology, Case Reports in interventional Cardiology. Invasive Cardiology is a branch of cardiology surgery performed on heart and vascular care through open surgery or percutaneous procedures. This type of surgery replaces the traditional way of surgery. The most common involving the surgery of the heart is under x-ray visualization.

Case Reports in Invasive Cardiology Journal is a peer-reviewed scientific Invasive Cardiology journal serving clinicians who treat cardiovascular disease. will consider for publication suitable articles on topics pertaining to the invasive or interventional treatment of patients with cardiovascular disease. The journal provides information on novel findings in the field of Myocardial Infarction, Pericardial Disease, Peripheral Arterial Disease (PAD), Pharmacology, Pre-Clinical Research/Basic Science, Prevention/Cardiovascular Risk, Pulmonary Hypertension, Valvular Heart Disease, Vascular Medicine, Heart Failure, Acute Heart Failure, Advanced Heart Failure/LVAD/Transplantation, Hypertension, Images in Cardiology, Cardiac Magnetic Resonance Imaging, Contrast Echocardiography, CT Coronary Angiography, Echocardiography - 3D, TEE, Nuclear Cardiology/PET, Stress Echocardiography, Imaging Vignette, Carotid Interventions.

Case Reports in Invasive Cardiology Journal is a publication intended to further progress of science, usually by reporting new research, reviews, editorials, and scientific papers across a wide range of scientific fields. Journals contain articles that are peer reviewed, in an attempt to ensure that articles meet the journal's standards of quality, and scientific validity. Each such journal article becomes part of the permanent scientific record. Case Reports in Invasive Cardiology Journal is an open access devoted to the most recent progression in Invasive Cardiology. The objective of this journal is to give a stage to researchers and academicians everywhere throughout the world to push, impart, and talk about different new issues and advancements in diverse ranges of Invasive Cardiology.

Journal Scope and Keywords: Journal of Clinical & Experimental Cardiology, Angiology: Open Access, Arrhythmia: Open Access, Journal of Cardiovascular Diseases & Diagnosis, Journal of Invasive Cardiology, Journal of Noninvasive Cardiology, Annals of Intensive Care, American College of Cardiology.

Manuscript Submission

Authors are requested to submit their manuscript by using Online Manuscript Submission Portal:

[casereportsjournal]

Pediatric Cardiology Case Reports Journal | PubMed Indexed

Pediatric Cardiology Case Reports Journal publishes case reports in pediatric cardiology journal, images in pediatric cardiology journal, surgery in pediatric cardiology, journal of pediatric cardiology imaging, pediatric heart journal etc. Paediatric Cardiology Case Reports accepting articles based on original research on basic and clinical sciences related to Pediatric Cardiology. Pediatric Cardiology Case Reports Journal also features review articles, critiques, controversies, methods, technical notes, selected case studies s and articles of special nature. 

Pediatric Cardiology Case Reports

Pediatric Cardiology Case Reports Journal offers peer-reviewed articles on Pediatric Cardiology. Pediatric Cardiology Case Reports Journal also supports articles written based on clinical or experimental research to add value and professionalism. Its editorial mission is to focus on prevention and rectification of Pediatric Cardiology. Clinical papers emphasizing medical and surgical aspects of all aspects of heart disease in infants, children, and adolescents, including embryology and anatomy, physiology and pharmacology, biochemistry, pathology, genetics, radiology, clinical aspects, investigative cardiology, electrophysiology and echocardiography, and cardiac surgery are acceptable for publication. Pediatric Cardiology Case Reports Journal particularly welcomes contributions from the specialists in the field Pediatric Cardiology.

Atherosclerosis Case Reports Journal

An arterial disease characterized by the deposition of fatty material on their inner walls. The exact cause of atherosclerosis is unknown. However, certain traits, conditions, or habits may increase the risk of developing atherosclerosis. The common risk factors are Unhealthy blood cholesterol levels, High blood pressure, Smoking, Insulin resistance, Diabetes, Overweight or obesity, Lack of physical activity, Unhealthy diet, Older age, Family history of early heart disease etc.

Congenital Heart Case Reports Journal

Congenital heart defect or congenital heart disease is an anomaly in the structure of the heart from the time of birth. The symptoms could vary depending on the specificity of the anomaly and also can be fatal.

Echocardiography Case Reports Journal

Echocardiogram, often referred to as a cardiac echo or simply an echo, is a sonogram of the heart. Echocardiography uses standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart.

Heart Transplantation Case Reports Journal in Children

Heart transplantation in infants and children is now a globally accepted therapy. Most of the cases of heart transplantation in children are due to congenital malformations. Survival in excess of 20 years after pediatric heart transplantation has been achieved. Most programs now report that more than 70% of their recipients survive at least 5 years.

Interventional Paediatric Cardiology Case Reports Journal

Interventional cardiology is a branch of cardiology refers specific Cather based techniques to various structural heart diseases, non-surgical procedures for treating cardiovascular disease. Interventional cardiologists use catheters – thin, flexible tube to repair damaged vessels or other heart structures, often avoiding the need for surgery. Many procedures can performed on heart by Catheterization. This most commonly involves the insertion of a sheath into the femoral artery and cannulising the heart under X-ray visualization. Cardiac catheterization is a test which used to evaluate your coronary arteries and heart valve function.

Newborns with Cyanosis Case Reports Journal

Cyanosis is a purplish-blue colour of the skin. Newborns with cyanosis are often called blue babies. Cyanosis means that there is less oxygen being carried by the body’s blood cells. In this situation, there may not be enough oxygen being carried to the tissues in the body. The colour is caused by high levels of reduced (deoxygenated) hemoglobin in the blood near the surface of the skin. Hemoglobin is the molecule that allows red blood cells to carry oxygen. Oxygenated hemoglobin is bright red, while deoxygenated hemoglobin is bluish. There are two main categories of cyanosis: central and peripheral. Central cyanosis causes a bluish colour in the lips, tongue, and skin, especially the fingers and toes. Peripheral cyanosis is seen only in the fingers and toes. Cyanosis caused by congenital heart conditions is often seen soon after birth, but sometimes it does not appear until a baby is older.

Pacemakers for Children

A device called Pacemaker can be placed in the chest or abdomen of a child or infant to control the abnormal heart rhythms using low energy electrical pulses.

Pediatric Cardiac Anesthesiology Case Reports Journal

It is the anesthetic practice focused on the preoperative, intra-operative and postoperative evaluation and management of pediatric patients or neonate with cardiac and intra-thoracic vascular disease.

Pediatric Cardiology Cases Journal

The Pediatric cardiologists face few challenging cases in their career. Those real life cases are a medium for the cardiology trainees to learn & grow. The identity of the patients is always altered or remains hidden. The cases are featured because most of them involve a diagnostic or therapeutic dilemma.

Pediatric Cardiology Statistics

In 2012, 512 heart transplants were performed in children worldwide. The proportion of pediatric transplant patients by recipient age has remained relatively stable for over last decade. Many more statistical researches are carried out and the facts around it make for alarming reading.

Pediatric Electrophysiology Case Reports Journal

The procedure of evaluating the electrical conducting system of the heart in infants, children, and adolescents is termed as Pediatric electrophysiology. Abnormalities of the electrical conducting system in children may result in arrhythmias palpitations, light-headedness, weakness, fatigue, or syncope.

Pediatric Heart Stroke Case Reports Journal

Strokes can happen anytime even in children, newborns, and unborn babies. Few medical conditions can increase the chances of stroke in children such as different heart disease or a heart surgery, abnormal or inflamed blood vessels in the brain etc.

Pediatric Open-Heart Surgery Case Reports Journal

Open-heart surgery is a surgery performed on heart that require a patient being placed on the heart-lung bypass machine. The heart can be stopped with a solution called "cardioplegia", which is a cold, high-potassium solution and protects the heart muscle while it is stopped. The heart itself can then be opened and repair can be accomplished in a bloodless, still environment.

Pediatric Pericarditis Case Reports Journal

Pediatric Pericarditis can be referred to as the infection involving the pericardium and leads to accumulation of pericardial effusion that, if untreated, can lead rapidly to hemodynamic collapse, tamponade, and death. The fluid is generally purulent but can be serosanguineous.

Pediatric Viral Myocarditis Case Reports Journal

Myocarditis, is an inflammatory disorder of the myocardium that is typically caused by a viral infection. Based on pathogenic findings Myocarditis can be classified as Active myocarditis, Borderline myocarditis, Nonmyocarditis.

Tachycardia & Bradycardia Case Reports Journal

Tachycardia & Bradycardia are the two very basic forms of Arrhythmia. Tachycardia is the medical condition in which the heart rate is faster than normal. The heart rate in the upper chambers or lower chambers of the heart, or both is increases.

If you have any special requests or queries regarding our services, visit our site for more information about Cambridge City Publishers - Pediatric Cardiology Case Reports - https://www.cardiologycasereportsjournal.org/journal/Pediatric-Cardiology-Case-Reports.html

[trustown]

Chimera biology

#Chimera biology trial

#Chimera biology license

7,8 In experimental cardiac allografts, chimerism has been implicated in arteriosclerosis of the transplant, 9,10 and human valvular grafts have been shown to be colonized by fibroblasts from the host. 4-6 So far, the analysis of chimerism in the transplanted heart has focused primarily on hematolymphopoietic and immune cells, and migration of leukocytes and T lymphocytes from the allograft to the recipient and from the host to the donor heart has been demonstrated. Human chimerism is now well recognized - for example, in the migration of fetal cells into the blood of the mother during pregnancy 3 and the two-way migration of cells between transplanted organs and their recipients. 1 Subsequently, interspecies chimeras (such as sheep–goat chimeras) were produced. As is often the case, art and imagination preceded science, and in the 1970s the development of chimeric mice became the goal of many laboratories. Only a few decades ago, we would have thought of these creatures exclusively as figments of our imagination. In biology, a chimera is an organism formed from aggregates of genetically different groups of cells derived from the same or different species. It is from this fascinating and mysterious mixture of animal and human that the scientific term originated. In addition to these interspecies animal chimeras, human–animal hybrids were common in Greek mythology the centaurs, the sirens, and the Minotaur are famous examples. In ancient Greece, chimeras were mythical monsters - part lion, part goat, and part snake. The most trusted, influential source of new medical knowledge and clinical best practices in the world.

#Chimera biology license

Information and tools for librarians about site license offerings. Valuable tools for building a rewarding career in health care. The authorized source of trusted medical research and education for the Chinese-language medical community. The most advanced way to teach, practice, and assess clinical reasoning skills. Information, resources, and support needed to approach rotations - and life as a resident. The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams. NEW! Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Ĭoncise summaries and expert physician commentary that busy clinicians need to enhance patient care.

#Chimera biology trial

NEW! A digital journal for innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[saltytyphoonstarlight]

Organ Preservation Market Value to Cross $ 455 Mn in 2032

According to a new analysis from FMI, the Organ Preservation Market is likely to reach US$ 455 Million in revenue by 2032, from US$ 230 Million in 2021, registering a strong 6.4% CAGR during the forecast period.

The rising incidence of chronic illnesses has a direct impact on the adoption of organ preservation, according to the findings of this study. The practice of conserving healthy organs removed from donors’ bodies is known as organ preservation. Organs are removed from the donor’s body, stored for transit, and then transplanted into the recipient’s body without causing major damage. Donor organ quality is strongly influenced by organ preservation for transplantation, which has a direct impact on a patient’s morbidity and survival rates following transplantation. One of the important reasons driving the organ preservation solutions market growth is the rising incidence of chronic illnesses, as well as the growing elderly population throughout the world.

Static cold storage organ preservation treatments are becoming more common as a result of the rising number of organ failures caused by diabetes, cardiovascular illnesses (CVDs), obesity, and other serious medical problems. Innovative and sophisticated strategies for organ preservation, such as NMP, are working as a growth-inducing agent.

Such strategies help to reduce the risk of reperfusion damage following transplantation and enhance static cold storage organ preservation results in clinical and experimental research. Furthermore, a growing number of government and non-government regulations and activities to encourage organ donation are favorably boosting the organ preservation solutions market growth.

The market is also being pushed forward by the growing number of people who volunteer to donate their organs for transplantation and research. Other factors such as increased research and development (R&D) as well as substantial developments in the global organ preservation market are expected to considerably contribute to market expansion.

Key Takeaways:

When the liver is no longer functioning, a preservation injury liver transplantation, also known as a hepatic transplant, can potentially preserve a person’s life. A doctor may also recommend a liver transplant to a patient who has reached the final stage of liver disease.

American Journal of Transplantation article, individuals who have a liver transplant had an 89% likelihood of survival after one year. The increasing need for organ transplantation is driving the global organ preservation market throughout the area.

Around 114,000 people in the United States are now on the waiting list for a life-saving organ transplant, according to the American Transplant Foundation. Each day, on average, 20 individuals die due to a scarcity of accessible organs for transplantation.

Competitive Landscape:

The global organ preservation marketis dominated by companies such as Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut (Netherlands).

Key Market Segmentation Covered:

By Solution:

University of Wisconsin Solution (UW Solution)

Custodial HTK

Perfadex

Other Solutions

By Technique:

Static Cold Storage

Hypothermia Machine Perfusion

Normothermic Machine Perfusion

By Organ Type:

Kidney

Liver

Long

Heart

Pancreas

By End User:

Organ Transplant Centres

Hospitals

Speciality Clinics

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East and Africa (MEA)

For More Information: https://www.futuremarketinsights.com/reports/organ-preservation-market

[finishinglinepress]

FLP POETRY BOOK OF THE DAY: Chimera by Brad Buchanan

TO ORDER GO TO: https://www.finishinglinepress.com/product/chimera-by-brad-buchanan/

Few people have survived the nightmare of a stem cell transplant gone sideways. Fewer still have had the audacity to write poetry about the miraculous yet bewildering experience of becoming a genetic chimera. Brad Buchanan breaks this taboo and offers us eloquent, surrealistic, and profoundly moving lyrics about his dramatic transformation and amazing recovery. The result is CHIMERA, one book of poetry you will never forget.

Brad Buchanan’s writings have appeared in more than 200 journals, and he has published three previous book-length collections of poetry: The Miracle Shirker (Poet’s Corner Press, 2005), Swimming the Mirror: Poems for My Daughter (Roan Press, 2008), and The Scars, Aligned: A Cancer Narrative (Finishing Line Press, 2019). Now Emeritus Professor of English at Sacramento State University, he has also published two academic books and numerous scholarly articles. His most recent book is a medical memoir entitled Living with Graft-Versus Host Disease: How I Stopped Fighting Cancer and Started Healing (Armin Lear Publishing, 2021). He was diagnosed with a rare form of T-cell lymphoma in February 2015, and after chemotherapy and radiation, he underwent a stem cell transplant in early 2016. The transplant, though successful, brought on temporary vision loss and disability, a compromised immune system, and an ongoing illness: acute, then chronic, graft-versus-host disease (GvHD). Late in 2016, he underwent an experimental treatment through a clinical trial for malignant B-cell lymphoma (caused by the Epstein-Barr virus); he is currently in remission.

ADVANCE PRAISE FOR Chimera by Brad Buchanan

CHIMERA, Brad Buchanan’s fourth book of poems, tells in lyrically oblique confessions and hallucinatory vignettes the difficult but nevertheless wonderful history and aftermath of the author’s 2016 stem cell transplant. This transplant, after a rocky and near-fatal beginning, enabled him to survive a malignant blood cancer through becoming a genetic chimera (his DNA was altered through the successful engraftment of his brother’s stem cells). It has also left him and his family to deal with many subsequent challenges: the dreaded return of lymphoma, a chronic illness (graft-versus-host disease) and many conflicting emotions. CHIMERA is a testament to the enduring power of poetry to capture and overcome moments of suffering and confusion, and a document of the serenity that the acceptance of illness and disability can offer.

–Joshua McKinney, author of MAD CURSIVE (Wordcraft of Oregon, 2012) and SMALL SILLION (Parlor Press, 2018)

Brad Buchanan‘s painfully stunning new collection, CHIMERA, continues his explorations of the monstrosities that cancer can create in the lives of human beings as they struggle through invasive testing, treatments, recovery, and the hope of being cancer-free that stem cell transplants offer. Buchanan…documents, reports, questions, disputes both himself and the world cancer and chimerism force him to confront. He helps us see and feel in a most visceral way what it means—for him, for us, for those he loves and those who love him—to be engaged in this struggle. “Cancer is not your standard bully, / it will not back down if confronted / with sufficiently brave defiance. / It doesn’t have a nervous system / to mobilize or sympathize. / The only martial arts it knows/ are patience, stealth and resilience.” These poems will surprise you with their tenacity, empathy and ingenious language.

–Susan Kelly-DeWitt, author of SPIDER SEASON (Cold River Press, 2016) and GRAVITATIONAL TUG (Main Street Rag Publishing, 2020)

CHIMERA is Brad Buchanan’s poetry of recovery after the medical and emotional ordeals he detailed so powerfully in his previous collection THE SCARS, ALIGNED (Finishing Line Press, 2019). The visceral realism and honesty of that volume are once again on display… two bitter, glittering prose poems bring Shakespeare’s Hamlet and Lear into the hospital to anatomize collapsing bodies and minds, in cynical and often hilarious tones… And some of the finest poems in the volume are the stunning pastiches of Emily Dickinson, who has given Buchanan a stanza that works like a knife edge to pare away all the sentiment and obscurity of an approach to—and a last-minute shying away—from death… The bleakest poems here could not have been written except from the perspective of a survivor husband and father, catching his breath in the outside world, looking back in astonishment… noticing the world of the healthy and loving and beautiful again.

–Brian Trehearne, Professor of Canadian Literature, McGill University

Please share/please repost [PROMO]#flpauthor #preorder #AwesomeCoverArt #poetry #read #poetrybook #poems

[coochiequeens]

By David McFadden

It’s been nearly seven years since the world’s first successful birth after a human womb transplant. Since that medical milestone, the experimental procedure has seen such significant clinical advances that over 60 uterus transplants have been performed in women across the globe, resulting in at least 18 live births.

Now a new publication in the journal Bioethics makes the case that research trials should consider including transgender women in this evolving fertility frontier, not just genetic women – that is, people with XX chromosomes.

“There isn’t an ethical reason why they should be denied access to the procedure,” said Dr. Jacques Balayla, an obstetrician-gynecologist and clinician scientist at McGill University who was the lead author for the paper published Feb. 20. The idea of transgender women carrying pregnancies is a paradigm-altering concept that would surely lead to religious and social objections. But Balayla notes that physicians were accused of “playing God” when in-vitro fertilization and similar procedures to promote pregnancy ramped up decades ago.

During a recent interview, Balayla said he and his four co-authors believe that transgender women should have the opportunity to experience pregnancy regardless of the circumstance of their birth.

“A woman who is born without a uterus and a man who transitions into a woman because of gender dysphoria have a similar claim to maternity if we consider them to have equivalent rights to fulfill the reproductive potential of their gender,” Balayla said. “And I think that we should.”

While still theoretical, it appears that implantation of a donated uterus and gestation in the body of a transgender individual should pose no physiological barrier if various conditions are met, according to Balayla.

Currently, uterus transplants are rare, experimental surgeries using organs from either living or dead donors. Following a successful pregnancy, transplant recipients always deliver babies via caesarean section. The donated organ – the only temporary transplant in medicine – is later surgically removed.

The motivation behind the new paper is to provoke conversations and raise awareness about the potential for uterus transplants among the transgender population. Balayla hopes to pave the way for an in-depth ethical framework assessing what circumstances should be met for those seeking the procedure.

This most recent paper expands on “The Montreal Criteria for the Ethical Feasibility of Uterine Transplantation,” an ethical framework published in 2012 designed to assess whether a woman could be considered a transplant candidate. That list of criteria stated that a uterus recipient should be a “genetic female of reproductive age.” Balayla is the primary investigator of the “Montreal Criteria”, which were developed at McGill and adopted as an international standard at the time, paving the way for the first successful human trials of uterine transplantation in medical history.

The new paper proposes added bioethical considerations for transgender individuals: They should expect to be able to share “normative experiences” enjoyed by others, those with gender dysphoria could feel physiologically complete with this transplanted reproductive organ, and a thorough examination of the medical risks must be done.

Balayla believes the time has arrived to advance a rights-based ethical framework for transgender women due to successes the medical community has achieved in recent years developing pregnancies, achieving safe births, and preventing graft rejection among uterus transplant recipients.

As transgender rights gain increasing mainstream acceptance, the political and social environment could also be ripe for broadening the scope of the surgical innovation. The paper suggests a transgender woman could possibly undergo a uterus transplant sometime in the future if an ethical framework is absorbed into clinical practice and research trials demonstrate the safety and success of uterus transplantation in this population.

“The Montreal Criteria and uterine transplants in transgender women,” by J. Balayla, Y. Gil, etc. was published in the journal Bioethics February 7, 2021. https://doi.org/10.1111/bioe.12832

And what about the children that could be born from these transplants? What developmental issues will they have from the drugs needed for the body to not reject the uterus or the fetus? What about the hormones women produce naturally during pregnancy? A woman’s organs adjust has the uterus grows, would a mans?

[nursingwriter]

Islet Transplantation Pancreatic Islet Transplantation Advancements in the areas of beta cell replacement and islet transplantation are slow in coming and the latest long-term success rates are disappointing, as less than 14% of transplant recipients remain free of insulin therapy after two years (Mayo, p. 1). In type 1 diabetes, the body destroys its own insulin producing cells. The body's immune system attacks and destroys cells in the pancreas called beta cells. These cells are contained within small islands of endocrine cells called pancreatic islets. In 1993 the Diabetes Control and Complications Trial (DCCT) established the modern standard of care for the medical management of type 1 diabetes mellitus. The DCCT assigned 1441 patients to intensive or conventional treatment. The first step included daily determinations of blood glucose levels several times daily at home by finger stick; then daily injections of long-, intermediate-, and short-acting insulin; accompanied by dietary and psychological support (Robertson, p. 694). Diabetic complications may include hypoglycemia, diabetic hyperosmolar syndrome, diabetic ketoacidosis, neuropathy, nephropathy, retinopathy, heart and blood vessel disease, and increased risk of infection. Controlling the disease is difficult. Monitoring blood glucose, eating a healthy diet, getting daily exercise, and maintaining a healthy weight are part of maintenance. Medical therapies for managing diabetes include the use of insulin to manage type 1 and type 2 diabetes and the use of sulfonylureas, meglinitides, biguanides, alpha glucosidase inhibitors, thiazolidinediones, and drug combinations to manage type 2 diabetes (Collazo-Clavel, p. 5). For decades, researchers have searched for ways to restore blood sugar control through human islet transplantation, a procedure in which only the islets that contain insulin-producing beta cells are transplanted. In 2000, the Edmonton Protocol brought attention to a novel approach for islet transplantation. This transplantation method used a larger quantity of islets and a combination of drugs that was less toxic to suppress the immune system. Healthy islets are isolated from a donor pancreas, purified, and then infused through a small tube into the portal vein of the liver. Patients must take immunosuppressive drugs to keep their bodies from rejecting the new islets. When successful, islet transplantation can restore normal blood sugar without the need for insulin injections and can improve quality of life. Islet transplants are still experimental, so they are available only to people who participate in a clinical study and meet specific criteria (U.S., p. 1). Replacing these cells via transplantation has been the subject of research for many years. Transplantation of beta cell containing islets is less invasive than transplanting a whole pancreas, which was the established procedure before 1993. In a procedure called islet transplantation, islets are transferred into a faulty pancreas from a healthy donor pancreas. The beta cells in these islets begin to make and release insulin, once implanted. Researchers hope that islet transplantation will help people with type 1 diabetes live without daily injections of insulin. (Pancreatic, p. 1) The Islets of Langerhans The pancreas makes enzymes and insulin that help digest and use food. Spread over the pancreas are clusters of cells called the islets of Langerhans. Islets are made up of two types of cells: alpha cells, which make glucagon, a hormone that raises the level of glucose (sugar) in the blood, and beta cells, which make insulin. Insulin, a hormone, helps the body use glucose for energy. If beta cells do not make enough insulin, diabetes develops. In type 1 diabetes, an autoimmune process causes insulin shortage by the body's immune system destroying the beta cells. Having reported their findings in the June 2000 issue of the New England Journal of Medicine, researchers at the University of Alberta in Edmonton, Canada, continue to use the Edmonton protocol to transplant pancreatic islets into people with type 1 diabetes. In 2000, a multi-center clinical trial of the Edmonton protocol for islet transplantation took place, and the promising results were announced. According to the Immune Tolerance Network (ITN), in June 2003, about 50% of the patients remained insulin-free up to 1-year after receiving a transplant. A clinical trial of the Edmonton protocol also was conducted by the ITN, funded by the National Institutes of Health and the Juvenile Diabetes Research Foundation International. (Pancreatic, p. 1). This year (2006), further trials on an international scale were reported in the New England Journal of Medicine. Believing that islet transplantation offers the best potential to improve glycemic control in type 1 diabetics, an international, multicenter trial to explore the feasibility and reproducibility of islant transplantation was done with the use of a single common protocol, the Edmonton protocol. 36 subjects with type 1 diatetes mellitus underwent islent transplantation at nine international sites. Islets from the pancreases of deceased donors were transplanted within 2 hours after purification, without culture. The goal was defined to be insulin independence with adequate glycemic control after one year following the final transplantation. Of the 36 subjects, 44% met the goal, 28% had partial function and 28% had complete graft loss. The 21 subjects who attained insulin independence had good glycemic control throughout the trial. 76% of these, however, required insulin again at two years, while 31% remained insulin-free at two years (Shapiro, p. 1330). In this procedure, researchers use specialized enzymes to remove islets from the pancreas of a deceased donor. Because the islets are fragile, transplantation occurs very soon after they are removed from the deceased donor. (Pancreatic, p. 1) Ultrasound is used by the surgeon during the transplant to guide placement of a small plastic tube (catheter) through the upper abdomen into the liver. The islets are injected through the catheter into the liver. The patient may receive a local anesthetic or general anesthesia while the surgeon does the transplant through a small incision. Risks include bleeding or blood clots. It takes awhile for cells to attach to new blood vessels in the recipient patient, to begin releasing insulin. The doctor orders tests to check blood glucose levels after the transplant, and insulin may be needed until control is achieved.(Ibid.) Transplantation: Benefits, Risks, and Obstacles Islet isolation and purification, transplantation, and other new strategies toward tolerance induction have been researched in recent years. Islet cell transplantation can be performed as a percutaneous minimally invasive procedure. Islets are infused into the liver via the portal vein. This transplantation modality could circumvent the organ shortage that prevents most patients with diabetes who are eligible from pancreas transplantation from actually receiving a graft. The graft offers the possibility of maintaining a healthy pancreas without chronic immunosuppressive drugs when the induction of donor-specific tolerance or immuno-isolation emerge as clinical strategies (Sperling, pp. 529-552). The goal of islet transplantation is to infuse enough islets to control blood glucose level without insulin injection. A typical transplant requires about 1 million islets, extracted from two donor pancreases for an average-size person (70 kg). Because good control of blood glucose may slow or prevent progression of diabetic complications such as nerve or eye damage, a successful transplant may reduce the risk of these complications. But a transplant recipient still needs to take immunosuppressive drugs to stop the immune system from rejecting the transplantation. (Pancreatic, p. 1) Researchers seek new approaches to allow successful transplantation without immunosuppressive drugs, "thus eliminating the side effects that may accompany their long-term use." (Ibid.) Nine patients who became diabetic after upper-abdominal exenteration and liver transplantation were given pancreatic islet-cell grafts obtained from the liver donor (eight cases), a third-party donor (one), or both (four). Two of the diabetic patients died of infections after 48 and 109 days, and a third patient died of tumor recurrence after 178 days. The other 6 survived 101-186 days postoperatively, and five remained insulin-free or on insulin only during night-time parenteral alimentation. C-peptide increased 1.7 to 3.3 fold in response to intravenous glucose in these five patients who have had glycosylated hemoglobin in the high normal range. The kinetics of the C-peptide responses to intravenous glucose in all eight patients revealed no first-phase release and delayed peak response consistent with transplantation and/or engraftment of a suboptimal islet cell mass. "The longest survivor, who requires neither parenteral alimentation nor insulin, is the first unequivocal example of successful clinical islet-cell transplantation." (Tzakis, p. 1323) Rejection is the biggest problem with any transplant. The immune system is programmed to destroy bacteria, viruses, and tissue it recognizes as "foreign," including transplanted islets. Immunosuppressive drugs are needed to keep the transplanted islets functioning. Immunosuppressive Drugs The Edmonton protocol uses a combination of immunosuppressive drugs, also called antirejection drugs, including dacliximab (Zenapax), sirolimus (Rapamune), and tacrolimus (Prograf). Dacliximab is given intravenously right after transplantation and discontinued. Sirolimus and tacrolimus, the two main drugs that keep the immune system from destroying the transplanted islets, must be taken for life (Pancreatic, p. 1). In the 35 years since the first vascularized (using blood vessels) pancreas transplant was performed in Minneapolis, Minnesota to prevent recurrent nephropathy (kidney disease) in a concomitant renal (kidney) transplant, an estimated 12,000 procedures have been performed in this country. This number is nevertheless insignificant compared to the estimated one million patients with type 1 diabetes. However, what was once a slow journey has recently gathered momentum with the introduction of "more flexible immunosuppression protocols, the ability to individualize surgical options to patient needs, and the dramatic improvement of isolated islet transplantation results." (Allen, p. 3485) Researchers use pancreas transplant options and advanced surgical techniques, but the donor pancreas and surgical complications, as well as the type of immunosuppression affect the outcome of islet transplantation. The immunosuppressive drugs have significant side effects and long-term effects are still not known. Known side effects of immunosuppressive drugs include mouth sores and gastrointestinal problems, such as stomach upset or diarrhea. Patients also have experienced increased blood cholesterol levels, decreased white blood cell counts, decreased kidney function, and increased susceptibility to bacterial and viral infections. Taking immunosuppressive drugs increases the risk of tumors and cancer as well. Progress on whole pancreas and beta cell transplantation has been hampered by the lack of available organs and the question of immunosuppression. The Center for Islet Cell Transplantation is a project with the goal of successful transplantation of beta cells without immunosuppression. Alternative approaches to islet transplantation under investigation include mixed bone marrow chimerism and co-stimulatory blockade. Another alternative to islet transplantation pursued for many years with varying success is the approach of shielding the islets from the immune system with a physical barrier while allowing the islets to receive nutrients and the insulin generating signals they need to produce the necessary insulin, then moving them through the barrier to the bloodstream. Techniques for accomplishing this include microencapsulation and a bioartificial pancreas. Other aspects that investigators are investigating include alloreactivity and autoreactivity. Also, who might benefit most from transplantation needs to be addressed (Clark, p. 52). Insulin-secreting pancreatic beta cells derived from stem cells -- pending availability -- may be eventually transplanted into patients to help maintain blood glucose homeostasis. The relative success of the transplantation of cadaveric beta cells into patients with type 1 diabetes provides support for this approach (Stanier, p. 521) An islet cell transplant may be an option for severe type 1 diabetes that can not be effectively managed with insulin or leads to complications. Because the procedure is still considered experimental in the United States, receiving it usually means participating in a clinical trial. Available organs usually are first allocated to people waiting to receive whole pancreas transplants. If a patient is accepted into a trial, they will need to wait for a donor pancreas. If a match can not be made, an organ is then allocated to a person on the islet cell transplant list. What happens during and after the transplant? An islet cell transplant begins with technicians extracting and purifying islet cells from a donor pancreas. Often, two or more donor organs are needed to accumulate enough islet cells for a single complete transplant. An interventional radiologist performs the actual islet cell transplant. This specialist and the radiologist direct a tube through an opening made in the abdomen to the portal vein, a blood vessel leading into the liver. They then infuse the islet cells through the tube to the liver, where the cells take up residence in the organ's small blood vessels. The liver is a good site for the islet cell transplant because it is more accessible than the pancreas, and the cells produce insulin well in that environment (Mayo, p. 1). Possible risks during surgery include bleeding or blood clots. After the transplant, the new islet cells need time to start working. The transplant team closely monitors blood sugar level and give insulin as needed. If the transplant is successful, the amount of insulin needed is gradually reduced as new cells take over. Because the immune system may try to reject new cells, patients take medications that suppress the immune system. These medications may cause noticeable side effects, such as weight gain, acne, facial hair, stomach upset or diarrhea, but the effects decrease as time goes on. The post-transplant treatment is a delicate balancing act between preventing rejection and managing unwanted side effects. A doctor monitors treatment of the patient closely and adjusts medication and care as needed. Intensive care also fosters higher success rates. (Mayo, p. 1) Clinical outcomes in terms of secondary complication rates were much better in the intensively treated group than in the conventionally treated group. Therefore, intensive treatment became the norm. More recent improvements in home care have also improved outcomes (Robertson, p. 694). Intensive care includes pancreas and islet cell transplantation. In the 35 years since the first vascularized (with blood vessels) pancreas transplant was performed in Minneapolis, Minnesota to prevent recurrent nephropathy (kidney disease) in a concomitant renal (kidney) transplant, an estimated 12,000 islet transplantation procedures have been performed in the U.S. While this represents a major achievement, it is insignificant compared to the estimated one million patients with type 1 diabetes. The initially slow journey has gained momentum with the dramatic improvement of isolated islet transplantation results. With more flexible immunosuppression protocols, and the ability to individualize surgical options to patient needs, numbers have improved when intensive care is utilized (Allen, p. 3485). A major obstacle to widespread use of islet transplantation is the shortage of islet cells. The supply available from deceased donors will be enough for only a small percentage of those with type 1 diabetes. Researchers pursue avenues of alternative sources, such as creating islet cells from other types of cells. New technologies may be employed to grow islet cells in the laboratory. Limitations of Islet Transplantation Published information shows several modifications of the Edmonton Protocol have been performed in over 15 centers involving over 160 patients worldwide. Patients who respond well to islet transplantation report being free of the need for insulin for about one year, on average, with the longest case being 7 years. This is similar to the rate of insulin independence achieved following whole pancreas transplantation. Although results from clinical studies appear promising, there are significant issues that remain before the technique can be considered for widespread application: Limited islet supply remains an obstacle. Only a limited number are suitable for transplant, based on the number of pancreas donors in the United States each year. Techniques to isolate islets have not been perfected (U.S.). Denise Faustman and colleagues at Massachusetts General Hospital (MGH) have an approach that identifies and selectively eliminates only the faulty cells of the immune system that mistakenly destroy healthy insulin-producing beta cells. The research has only been conducted on mice, but the Federal Drug Administration and the MGH have approved plans for a clinical trial to correlate the mouse model findings to type 1 diabetes in humans (4). Immunosuppression toxicity: After receiving a transplant, patients receive potent immunosuppressive medications for the rest of their lives. These medications often have serious side effects, so patients also contend with a higher risk of infections resulting from a weakened immune system. Normal blood sugar levels are not achieved. Although islet transplant patients appear to have better control of their blood sugar levels compared to those who achieve it with insulin, diet, and exercise, only a small percentage of transplant patients achieve normal blood sugar levels. Long-term safety numbers are questionable. Gaining access to the portal vein of the liver to transplant islet cells involves some risks as it is a difficult procedure. Immediate risks include portal vein thrombosis and bleeding. Long-term consequences are not known, but reports of hepatic steatosis have been documented. This happens when fat globules collect within the cells of the liver and cause the tissue to deteriorate and malfunction. Duration of islet allograft function may be exhausted. In addition to rejection by a patient's immune system, the transplanted islets are susceptible to aging. It is not known how long islets function after transplantation, and whether the patient may eventually need multiple transplants. Conclusion The effect of islet transplantation on diabetic complications remains a question. Controversy remains over whether a transplant actually stops or reverses secondary complications related to diabetes. It is also not clear whether transplantation may extend a patient's long-term survival rate (U.S.) Insulin independence is difficult to sustain with islet transplantation. The Edmonton protocol can successfully restore endogenous insulin production and glycemic stability in subjects with type 1 diabetes mellitus and unstable control. But even without insulin independence, persistent islet function following the procedure provides both protection from severe hypoglycemia and improved levels of glycated hemoglobin (Shapiro, p. 1330). (ClinicalTrials.gov number, NCT00014911 .) Fortunately, there are alternative solutions to the rejection of islets by the immune system that are currently being researched. Read the full article

[ganeshg]

Organ Preservation Market Is Set to Experience a Significant Growth Of 6.4% CAGR From 2022 To 2032

According to a new analysis from FMI, the Organ Preservation Market is likely to reach US$ 455 Million in revenue by 2032, from US$ 230 Million in 2021, registering a strong robust of 6.4% CAGR during the forecast period. The rising incidence of chronic illnesses has a direct impact on the adoption of organ preservation, according to the findings of this study.

The practice of conserving healthy organs removed from donors' bodies is known as organ preservation. Organs are removed from the donor's body, stored for transit, and then transplanted into the recipient's body without causing major damage.

Donor organ quality is strongly influenced by organ preservation for transplantation, which has a direct impact on a patient's morbidity and survival rates following transplantation. One of the important reasons driving the organ preservation solutions market growth is the rising incidence of chronic illnesses, as well as the growing elderly population throughout the world.

 Static cold storage organ preservation treatments are becoming more common as a result of the rising number of organ failures caused by diabetes, cardiovascular illnesses (CVDs), obesity, and other serious medical problems. Innovative and sophisticated strategies for organ preservation, such as NMP, are working as a growth-inducing agent.

Such strategies help to reduce the risk of reperfusion damage following transplantation and enhance static cold storage organ preservation results in clinical and experimental research. Furthermore, a growing number of government and non-government regulations and activities to encourage organ donation are favorably boosting the organ preservation solutions market growth.

The market is also being pushed forward by the growing number of people who volunteer to donate their organs for transplantation and research. Other factors such as increased research and development (R&D) as well as substantial developments in the global organ preservation market are expected to considerably contribute to market expansion.

Request a report sample to gain comprehensive insights @ 

https://www.futuremarketinsights.com/reports/sample/rep-gb-14363

Key Takeaways:

● When the liver is no longer functioning, a preservation injury liver transplantation, also known as a hepatic transplant, can potentially preserve a person's life. A doctor may also recommend a liver transplant to a patient who has reached the final stage of liver disease.

● American Journal of Transplantation article, individuals who have a liver transplant had an 89% likelihood of survival after one year. The increasing need for organ transplantation is driving the global organ preservation market throughout the area.

● Around 114,000 people in the United States are now on the waiting list for a life-saving organ transplant, according to the American Transplant Foundation. Each day, on average, 20 individuals die due to a scarcity of accessible organs for transplantation.

Competitive Landscape

The global organ preservation market is dominated by companies such as Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut (Netherlands).

● Paragonix Technologies will commercialize the LIVERguard Donor Liver Preservation System in the United States and Europe in 2021. This strategy increased the product options and geographic reach of Paragonix.

● In 2021, XVIVO Perfusion teamed with Contatti Medical (Brazil) to develop its company and have access to the largest network of transplantation clinics in Latin America, Brazil.

● Institut Georges Lopez (Igl) (France) increased its presence in India in 2021 by establishing a manufacturing plant in Cheyyar, Tamil Nadu, for the manufacture of medical equipment and treatments for organ preservation for transplantation.

● Transmedics gained premarket approval from the FDA in 2021 for the OCS Heart System, which is intended for use with organs donated after brain death (DBD).

● Dr Franz Köhler Chemie GmbH (Germany) engaged in a joint venture with Melchers Group and CICEL (Germany) in 2020 to create Köhler Pharmaceuticals (Beijing) Ltd. in China to distribute Custodiol HTK solutions for heart and transplant operations in the Chinese market.

[catilus]

A sinister doctor and his growing army of skeletons I drew on commission recently! More fantasy art, NPCs, awesome homebrew, and other cool stuff: https://www.patreon.com/Catilus

Name: Dr. Floridius Ohgden, Medical Practitioner and Necromancer

Floridius began his career as a surgeon before becoming an adventurer as he sought a method of eternal life for those not blessed with immortal flesh to go along with their immortal souls. This search led the doctor down a dark path as he sought out the secrets of life and death through experimentation. He would partner up with a rogue doctor running an illegal vivisection clinic where subjects were surgically experimented upon for increasing the pair’s medical knowledge. Eventually Floridius was arrested and served time in a Waterdeep prison for his crimes and his partner and instructor disappeared without a trace. After years of imprisonment, he was released and made for the fortress of Candlekeep where he would begin his studies anew. In exchange for his stay there he taught a class on biology and anatomy often performing vivisections on creatures for demonstrations... This was not a popular class for many reasons.

After months in Candlekeep, Floridius met a party of adventurers who were seeking a method to transition to the Nine Hells to track down a rogue angel who became an archduke of hell. Floridius saw this as an opportunity to study the immortal flesh of devils to further his studies, and so he requested to tag along, offering his medical expertise to the group as well as his skills with small blades to act as an excellent rogue.

The Hells ended up teaching the mad doctor quite a lot on immortality, but he was also falling further into the depths of corruption as he had met with and exchanged knowledge for knowledge with a bound and then freed flesh-shaping demon. The demon taught Floridius the art of fleshcraft and how to graft monster components onto himself and others.

After the party left the Hells, Floridius had multiple journals of notes on the study of immortality via fleshcraft, surgical replacement of organs, and other less than savory means. But he is no god, and thus his control of the immortal soul and its binding to mortal flesh is limited. So, his next goal was clear: transcend the limitations of his mortal coil, perform the ultimate necromantic rituals to bind his soul to an object, and transplant his organs to a fleshcrafted golem. With this he would become a lich like no other; an immortal flesh golem with the knowledge to grant this gift unto others. However, the pursuit of such ability has forever changed the mad doctor and his studies and research have no place in civilization.

What do you think? :)

Find the full HD version, plus tons of fantasy and SF art, D&D items, my 5e adventures and supplements (FREE for Patreon supporters!), NPCs, and more great stuff at my Patreon: https://www.patreon.com/Catilus

Join the Catilus Discord! https://discord.gg/catilus

Facebook: https://www.facebook.com/CatilusArt

Instagram: https://www.instagram.com/CatilusArt/

Twitter: https://twitter.com/CatilusArt

#Catilus #Patreon #dnd #OpenDnD #OpenRPG #art #fantasy #roleplay #RPG #TTRPG #magic #dog #skeleton #wizard #doctor